not used title
not used title
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints conducted research that found significant variability in treatment preferences among MS patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians.
It is widely acknowledged that patients with MS are different in terms of clinical needs, preferences and treatment goals. For MS patients, providing greater opportunity for successful management of the disease and its progression requires the availability of a broad range of therapeutic alternatives. Often, a treatment option that is effective and has few side effects in one MS patient may produce the opposite result in another due to the diverse nature of the disease. Additionally, different patients may require different treatments depending on their preferences or treatment goals – some patients may place more weight on slowing disease progression, while others may be concerned about safety and side effect profiles. Fortunately, as a result of treatment advances over the past several decades, a range of options are now available to meet the wide variety of needs of people with MS.
The variability in treatment needs and preferences among MS patients found in Real Endpoint’s research is also why population-level judgements of an MS treatment’s value, like the recent value assessment conducted by the Institute for Clinical and Economic Review (ICER), often fail to capture the true importance of these medicines to patients. ICER’s payer-centric value assessment also doesn’t capture significant differences in what patients value in MS treatments compared to what payers value in how MS patients are treated. If misused by payers and policymakers, ICER’s assessment could also impede successful management of MS by limiting patient and provider choice, which is critical to managing and slowing progression of the disease.
(Source: Real Endpoints, LLC, January 2017)
Key findings from Real Endpoints’ research include:
- MS patients define value differently than payers and physicians. Patients ascribe highest value to a medicine’s effect on MS symptoms (such as fatigue and walking difficulty) relative to a medicine’s efficacy. On the other hand, payers and physicians are more concerned with disease progression, effect on relapse rate and effect on severity of relapses.
- Patients are more concerned about a medicine’s safety characteristics (e.g., severity of side effects, interactions with other medications) than payers or physicians. Unfortunately, population-level judgements of value do not always align with the prioritization of patient preferences found in Real Endpoint’s research. Stakeholders who commented on ICER’s MS report noted that ICER emphasized efficacy over safety in its assessment.
- Patients are more concerned with out-of-pocket costs than payers, who are primarily concerned about the medicine’s effect on health care services needed to treat MS. ICER’s assessment focuses on the cost-effectiveness and short-term budget impact of an MS treatment. While this information is useful to payers, it fails to acknowledge the costs that matter to patients.
More information on Real Endpoints’ findings can be found here.
Lauren Neves
Lauren Neves is Vice President of Policy at PhRMA focusing on the value of cancer medicines, medication adherence, and payment and delivery reform. Prior to joining PhRMA, Lauren earned her law degree and worked as a market access and health policy consultant to health care and pharmaceutical clients.
Author Twitter
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
Reimagining patient access through meaningful policy reform
November 5, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
WTAS: Voters voice concerns about PBM abuses, call on policymakers to act
July 19, 2024
ICYMI: Voter priorities this election season
April 18, 2024
Four years later, Maryland board still hasn’t delivered for patients
February 12, 2024
Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients
February 7, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
ICYMI: WSJ — Same Drug, Two Prices: Why the Higher Price Prevails
November 15, 2023
ICYMI: Scott LaGanga and Matt Salo deliver a State of the Industry Report
October 25, 2023
Incomplete evaluations undermine patient access to transformational medicine
October 5, 2023
Word of the Month: AMR
September 27, 2023
New analysis shows PBMs use fees as a profit center
September 18, 2023
New PhRMA ad exposes yet another way PBMs get between patients and their medicines
September 5, 2023
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
July 26, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
4 key facts on medicine prices and spending
May 9, 2023
Americans want state policymakers to lower out-of-pocket costs
May 1, 2023
Policies need to address the growing threat of antimicrobial resistance
April 28, 2023
Three facts about health care spending
April 25, 2023
AHIP’s latest misinformation campaign & what it’s trying to hide
April 24, 2023
New global analysis shows patient access challenges around the world
April 12, 2023
States can support access to medicine as COVID-19 Public Health Emergency ends
April 5, 2023
Arkansas puts patients first with new share the savings law
April 4, 2023
New Report: More than 400 medicines in development for leading chronic conditions affecting older Americans
March 28, 2023
Holding pharmacy benefit managers accountable
February 23, 2023
Stopping pharmacy benefit managers from “gaming the system”
February 22, 2023
Recognizing National Glaucoma Awareness Month
February 1, 2023
ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference
January 19, 2023
In their own words: Insured Americans support policy reforms that address access and affordability concerns
December 14, 2022
ICYMI: PhRMA COO Lori Reilly speaks about the health care agenda for the next Congress
December 9, 2022
New Report: Nearly 800 medicines in development to treat chronic conditions
September 29, 2022
A key fact the White House is reluctant to admit
September 27, 2022
A key fact the White House is reluctant to admit
September 27, 2022
Navigating the patient experience: Burdens and barriers standing between patients and their care
September 12, 2022
New survey: Voters seriously concerned about fine print in reconciliation bill
August 12, 2022
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
August 10, 2022
Myth vs. Fact: The Senate’s latest price setting proposal
August 5, 2022
ICYMI: Patients across the country are sharing concerns about government price setting
August 3, 2022
The Senate’s latest price setting proposal will undermine U.S. economic growth
August 3, 2022
Celebrating Medicare’s 57th anniversary
August 2, 2022
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
August 1, 2022
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
July 29, 2022
The Senate’s latest price setting proposal will undermine: Our health care system
July 28, 2022
The Senate’s latest price setting proposal will undermine: American medical innovation
July 27, 2022
The Senate’s latest price setting proposal will undermine: Patient access to medicines
July 26, 2022
The Patient Perspective: Government price-setting harms patients
July 22, 2022
Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US
July 14, 2022
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
July 12, 2022
By the Numbers: Patients lose when the government sets prices
July 8, 2022
Patients win as West Virginia implements first-in-nation share the savings policy
July 8, 2022
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
June 16, 2022
PhRMA presents research at ISPOR 2022
May 26, 2022
Spotlighting a growing mental health challenge
May 9, 2022
Innovative contracts continue to gain traction and improve quality of care
May 2, 2022
Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities
April 27, 2022
Analysis: States can help patients save nearly $1,000 annually on their medicines
April 21, 2022
Veterans Affairs 101: Three charts show how the VA system differs from Medicare
March 11, 2022
Government price setting leaves behind families counting on new medicines
February 23, 2022
PhRMA submits comments urging CMS to withdraw coverage proposal
February 11, 2022
Medicaid 101: Three charts on access and spending
February 3, 2022
Government price setting won’t stop insurers from shifting costs to patients
February 2, 2022
New comments outline ways to counteract cost-shifting insurance trends
January 28, 2022
New study finds more than half of brand medicine spending goes to the supply chain and others
January 7, 2022
Making medicines more affordable: Preserving safety-net programs like 340B
December 17, 2021
Post-approval research save lives. Why is Congress trying disincentivize it?
December 17, 2021
A price control by any other name would still put patients at risk and threaten innovation
December 9, 2021
Making medicines more affordable: Making insurance work like insurance
December 8, 2021
Navigating the patient experience in the time of COVID-19
December 6, 2021
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
November 23, 2021
New poll shows Americans reject Medicare negotiation once they learn more about the policy
October 15, 2021
New report shows more than 260 medicines in development to fight neurodegenerative diseases
October 12, 2021
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
October 7, 2021
PhRMA releases 2021 industry profile
September 20, 2021
Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs
May 17, 2021
Four solutions Americans support to make health care more affordable
May 13, 2021
H.R. 3 threatens access to medicines, future innovation and American jobs
May 4, 2021
Getting the 340B program back on track in 2021
March 10, 2021
Growth in innovative, value-based contracts holds promise for the health system and for patients
September 24, 2020
Innovative contracts drive access for patients and value for the system
September 9, 2020
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
April 20, 2020
Low-value health care costs $345B each year and provides little benefit
February 26, 2020
Addressing barriers that inhibit value-based contracts
February 21, 2020
Guest post: H.R.3 is the wrong approach to help patients like me
November 26, 2019
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter
November 7, 2019
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
November 4, 2019
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
September 4, 2019
"If Washington isn’t careful, we might leave innovation behind"
June 24, 2019
5 Ways to improve ICER’s value assessment framework
June 20, 2019
Assessing value top of mind at ISPOR 2019
June 5, 2019
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
March 20, 2019
Value assessments should include all the outcomes that matter to patients and families
February 20, 2019
PhRMA comments to administration on Medicare Part D proposed rule
January 25, 2019
Keep the Six Protected Classes, protected
January 22, 2019
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
October 2, 2018
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers
September 19, 2018
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
September 13, 2018
Guest post: Developing new payment models to ensure patients have access to high-investment therapies
September 6, 2018
Number of value-based contracts continues to rise
August 27, 2018
How much do you know about Medicare Part B?
July 31, 2018
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
July 24, 2018
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
July 16, 2018
How ICER’s assessment of a new class of migraine treatments fails patients
July 10, 2018
Aspen Spotlight Health: Discussing the forefront of innovation
June 21, 2018
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
June 1, 2018
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
May 31, 2018
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches
May 29, 2018
Event tomorrow: Improving patient access to lifesaving medicines
May 22, 2018
Improve women’s health by treating the disease, not the pain
May 17, 2018
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
May 15, 2018
To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements
May 10, 2018
Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event
May 4, 2018
Reality check: Value-based contracts are good for patients
April 25, 2018
New report shows over 500 medicines in development for neurological disorders
April 18, 2018
Video: Barriers to results-based contracts
April 17, 2018
Improving care quality by engaging patients in shared decision making
March 22, 2018
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access
March 15, 2018
Fact Check Friday: The truth about the cost of 340B to patients
January 26, 2018
Ask About Adherence: Private-sector collaboration can lead to savings and care improvement
January 25, 2018
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
January 18, 2018
ICYMI: Why 2017 medicine approvals matter
January 12, 2018
Clarity around anti-kickback statute needed to promote innovative payment arrangements
January 10, 2018
Video: What is a results-based contract?
November 13, 2017
Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes
October 24, 2017
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
October 20, 2017
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
October 12, 2017
PhRMA Foundation recognizes inaugural Challenge Award recipients
October 6, 2017
Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care
September 21, 2017
The journey to better health care requires a holistic view
September 18, 2017
Medicare Monday: How Part B has evolved over the years
July 24, 2017
Modernizing FDA regulations to advance a value-driven health care system
June 8, 2017
A critical opportunity to prevent prescription drug abuse
June 2, 2017
PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines
June 2, 2017
ICYMI: Avalere and FasterCures develop new value framework from patient perspective
May 31, 2017
ICYMI: Innovative payment models helping provide patient access to new medicines
May 5, 2017
340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients
April 27, 2017
Trading fair means upholding the law: A focus on patents
April 18, 2017
Enforcing unmet trade obligations protects U.S. innovation
April 11, 2017
RA medicines often demonstrate far greater benefits to patients than initially understood
April 5, 2017
New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price
March 29, 2017
Medicare Monday: A discussion on affordability and access to medicines
March 27, 2017
17 years (and more) of medical discoveries
March 24, 2017
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care
March 6, 2017
ICYMI: New era of medicine initiative kicks off in Boston
February 22, 2017
Biopharmaceutical industry’s success reducing disparities for African Americans
February 16, 2017
PhRMA CEO talks White House meeting, innovation & jobs with POLITICO’s Pulse Check
February 9, 2017
VIDEO: PhRMA CEO discusses #GOBOLDLY campaign and White House meeting with CNNMoney’s Maggie Lake
February 3, 2017
The Value Collaborative: Advancing private market solutions to achieve better health, lower costs
January 31, 2017
Chronic Disease
Multiple Sclerosis
Patients
Policy Solutions
Value-Driven Health Care
The Value Collaborative
How do multiple sclerosis patients define value?
February 24, 2017